Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

Recruiting Phase 1 Phase 2 Interventional Study
Radiation-Induced Xerostomia and Hyposalivation
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
42 (estimated)
Sponsor
RiboX Therapeutics Ltd. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a first-in-human clinical study to evaluate the safety, tolerability and efficacy of RXRG001 administered in the ducts of the parotid glands in adult patients with radiation-induced xerostomia (dry mouth) and hyposalivation (reduced saliva production). In Part 1 of the study (open-label, single-arm), patients will receive unilateral administrations of RXRG001 in 3 single ascending dose co…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria\* 1. At least 18 years of age 2. Free from recurrence of your cancer and never have had another form of cancer for at least 2 years 3. Suffering from xerostomia and/or hyposalivation and have xerostomia symptoms which were not resolved after treatment for at least 3 months 4. Bot…
Contacts

RiboX Therapeutics Ltd.

617-999-8257

RiboX-SPRINX1-RX-RIX-CS101-Study-Mailbox@ribox-tx.com

CONTACT